Sherbrooke (Québec, Canada)– October 25th, 2017 Lumed, a leading-edge software firm with a mission to optimize infectious diseases clinical practice, improve antimicrobial governance, and enhance the quality of patient care, was acquired by bioMérieux, a world leader in the field of in vitro diagnostics. This acquisition marks a significant milestone, uniting both companies’ efforts to sell and distribute the Lumed Antimicrobial Prescription Surveillance System (APSS) and DATA software in Europe, Canada, and the US.

The two companies forge even stronger bonds with Lumed welcoming strategic equity investments by bioMérieux. This investment completes a funding round started earlier this year with participating entities including, notably, ACET Capital, Bank of Development of Canada for Quebec Regions, Desjardins, Economic Development Canada and Can-Export. Lumed is a business of the ACET accelerator that has seen direct benefits from the partnership between the University of Lyon and the University of Sherbrooke, which has enabled it to strengthen its link with bioMérieux more quickly.

Appropriate antimicrobial governance is essential in order for hospitals to provide proper patient care, control pharmacy costs and reduce antimicrobial resistance. The APSS is a computerized clinical decision-support system designed to assist antimicrobial stewardship teams to monitor clinical information, as soon as information becomes available, and verify that the ongoing treatment remains appropriate according to contraindications related to inappropriate drug–drug interactions, drug–bug or drug–laboratory mismatches, cheaper alternatives, maximum daily dose, maximum and minimum dose and frequency, maximum duration and route of administration while taking into account a number of critical patient-specific information. In a recently published study, the implementation of the software has demonstrated a sustained reduction of 20% of antimicrobial use over a 3 years period¹.

The deployment of the APSS globally by bioMérieux, in collaboration with Lumed, will reinforce even further the company`s leadership position in the fight against antimicrobial resistance by working closely with the hospital systems.

“We were deeply impressed by this innovative solution brought by a team of the highest quality. We look forward to working with Lumed by providing the commercial scale that allows to serve patients around the world,” said Alain Pluquet, bioMérieux’s Corporate Vice President, Chief Data Officer. “bioMerieux is committed to the fight against antimicrobial resistance, and this above and beyond the laboratory.

Our partnership with Lumed illustrates our approach of selective partnering to grow our Data Analytics business, with a continued focus and commitment on patient care.” “BioMérieux’s history and track record as leaders in microbiology are impressive. As they’ve successfully expanded their global footprint, they still maintain an intimate and respectful relationship with smaller, innovative companies like ours. I am convinced the synergies between our products and expertise will significantly improve patient care around the world” stated Vincent Nault, Co-Founder and CEO of Lumed.

« Nous avons été impressionnés par le caractère innovant de cette solution développée par une équipe d’une qualité exceptionnelle et nous avons hâte de travailler avec Lumed en fournissant une organisation commerciale permettant de servir les patients du monde entier », a déclaré Alain Pluquet, Directeur de l’unité Data Analytics de bioMérieux. « bioMérieux est engagé dans la lutte contre la résistance aux antibiotiques, et ceci au-delà du laboratoire. Notre collaboration avec Lumed illustre notre approche sélective de partenariat pour développer notre activité Data Analytics, dans un engagement continu au service de l’amélioration de la prise en charge des patients. »

« L’histoire et l’expérience de bioMérieux, en tant que leader en microbiologie sont impressionnantes. bioMérieux a depuis longtemps réussi à étendre sa présence à l’échelle mondiale tout en maintenant des relations étroites et respectueuses avec des entreprises plus petites et innovantes comme la nôtre. Je suis convaincu que les synergies entre nos produits et nos expertises amélioreront considérablement la qualité des soins apportés aux patients » a déclaré Vincent Nault, cofondateur et Président directeur général de Lumed.

[1] Nault V et al, J Antimicrob Chemother. 2017